MEDSIR is excited to announce that we have been selected to share 3 of our trials at ESMO Breast Cancer 2022! The conference will be held in Berlin, Germany from May 3rd through 5th and will offer both an in-person and a virtual platform experience. This multidisciplinary meeting provides an overview of new practice changing data as well as teaches clinicians how to integrate these new innovations into their daily practice to provide patients with the best possible care.
Our ATRACTIB trial will be presented in the Trial in Progress poster presentation displays. Both the Impassion130 and KEYNOTE-355 trials have demonstrated the substantial benefit of adding immune checkpoint inhibitors (ICIs) to chemotherapy for patients with metastatic triple negative breast cancer who have programmed death-ligand 1 (PD-L1)–positive tumors. However, with many patients still having a poor outcome, studies have started to explore the synergisms between ICIs, vascular endothelial growth factor (VEGF)–targeted agents, and standard chemotherapy. With encouraging preclinical and small clinical study results from the combination, the ATRACTIB trial is evaluating the safety and efficacy of first-line ICI atezolizumab in combination with paclitaxel, and bevacizumab in patients with metastatic triple negative breast cancer.
Presentation #: 205TiP
Abstract Title: ATRACTIB: A Phase II Trial of First Line (1L) Atezolizumab (A) in Combination with Paclitaxel (P) and Bevacizumab (B) in Metastatic Triple Negative Breast Cancer (mTNBC)
Session Information: Wed, May, 4th, 12:15 - 13:00, Exhibition area
Our CALADRIO trial will be presented in the Biomarkers and translational research and precision medicine Early breast cancer poster session. This study is an exploratory sub-study of our KELLY trial, which evaluated pembrolizumab and eribulin for HR+/HER2- metastatic breast cancer previously treated with anthracyclines and taxanes. Specifically, the CALADRIO study assesses the impact of gut and oral microbiota from these patients. Fecal and saliva samples were prospectively collected at baseline, after 3 cycles, and at the end of treatment for a subset of patients enrolled in the KELLY trial. Tumor response was grouped into clinical benefit and no benefit and shotgun metagenomic, and 16S rRNA gene sequencing were used to characterize samples.
Presentation #: 14P
Abstract Title: Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO
Session Information: Wed, May, 4th, 12:15 - 13:00, Exhibition area
The data from the secondary endpoint from the PHERGain trial will be presented as a mini-oral presentation. The PHERGain trial evaluated a chemotherapy-free approach of trastuzumab and pertuzumab in HER2+ early-stage breast cancer through an FDG-PET response–adapted strategy. FDG-PET “responders” were defined as patients who had a maximum standardized uptake value reduction of at least 40% in their target lesions after two cycles of trastuzumab and pertuzumab, according to the NeoALTTO study. This oral presentation will describe our analysis of the best cut-off for maximum standardized uptake value reduction for the optimal prediction of pathological complete response.
Presentation #: 93MO
Abstract Title: Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
Session Information: Tues, May 3rd, 17:08 - 17:15, Frankfurt Hall
We are eager to share our trials at this conference and would love to connect with you, please contact us if you’re attending ESMO Breast 2022 or if you want more information about any of the trials we will be presenting!
